Loading
Liver Disease Diagnosis and Treatment / Diabetes, Cardiovascular Risks, and Lipoproteins · Journal article
Nature Communications · September 2, 2026
Encouraging direction, but not yet definitive.
This latent class analysis identifies five genetically and clinically distinct MASLD subtypes replicated in an independent cohort, with differing risks for metabolic comorbidities, liver transplantation, and advanced fibrosis. The findings support MASLD heterogeneity and suggest opportunity for subtype-directed therapy, but remain observational and descriptive without prospective clinical validation or intervention trials.
Latent class analysis with independent cohort replication. Patients with metabolic dysfunction-associated steatotic liver disease from multi-year Mayo Clinic records on liver disease with linked genomic data; specific eligibility criteria not stated.. Mayo Clinic (United States).
Five distinct MASLD subgroups identified by latent class analysis and validated in independent cohort Subgroup C2 (male-predominant cardiorenal) and C3 (female-predominant obesity/mood) associated with high prevalence of type 2 diabetes, obesity, and sleep apnea Subgroup C4 (polygenic MASLD) characterized by lowest incidence of metabolic comorbidities and ischemic heart disease but highest rate of liver transplant
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These subtypes may enable risk stratification and personalized monitoring: C2 and C3 require aggressive cardiometabolic management; C4 warrants heightened surveillance for hepatic decompensation despite low metabolic burden; C5 needs early fibrosis and renal function monitoring. However, prospective studies validating clinical utility and testing subtype-specific interventions are needed before practice implementation.
A well-designed latent class analysis identifying five reproducible MASLD subtypes with distinct genetic and clinical profiles in independent cohorts, but a cross-sectional observational study without prospective clinical trials or hard outcome validation.
As stated by the source record.
Quoted from the source exactly as published.
These subtypes may enable risk stratification and personalized monitoring: C2 and C3 require aggressive cardiometabolic management; C4 warrants heightened surveillance for hepatic decompensation despite low metabolic burden; C5 needs early fibrosis and renal function monitoring. However, prospective studies validating clinical utility and testing subtype-specific interventions are needed before practice implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous condition with diverse etiologies and clinical presentations. Yet, a consensus of subtypes is lacking in MASLD. Based on latent class analysis of significant MASLD-related clinical variables, we identify five subgroups with distinct genetic, clinical, and risk profiles, which are well recapitulated in an independent cohort. Polygenic risk score and genetic variant analysis reveal genetic contributions across all subgroups. In particular, two subgroups, male-predominant cardiorenal (C2) and female-predominant with obesity and mood disorders (C3), are associated with high prevalence of type 2 diabetes, obesity, and sleep apnea. The latter also has relatively high usage of antidepressant medicine. On the other hand, the polygenic MASLD (C4) is characterized by the lowest incidence of metabolic comorbidities and ischemic heart disease. Nevertheless, this subgroup overall has the highest rate of liver transplant, which is likely driven, in part, by the combinatorial genetic effects of high-prevalent risk alleles in TM6SF2 and MBOAT7 together with low-prevalent protective allele in HSD17B13. Finally, the polygenic MASH subtype C5 shows increased risk of developing advanced fibrosis and acute renal failure. Together, our study provides key insights into MASLD heterogeneity, highlighting the opportunity for personalized therapies. From multi-year Mayo Clinic records on liver disease, researchers identified five distinct patient patterns. The method for generating liver disease subtypes is robust, producing transferable subtypes across diverse patient cohorts.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.